Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cachexia | 7 | 2022 | 54 | 2.930 |
Why?
|
| Muscular Atrophy | 8 | 2017 | 35 | 1.490 |
Why?
|
| Muscle, Skeletal | 8 | 2019 | 396 | 1.430 |
Why?
|
| Pancreatic Neoplasms | 6 | 2019 | 332 | 1.120 |
Why?
|
| Respiration, Artificial | 7 | 2017 | 190 | 1.120 |
Why?
|
| Diaphragm | 6 | 2017 | 22 | 1.100 |
Why?
|
| Reactive Oxygen Species | 8 | 2020 | 499 | 0.790 |
Why?
|
| Chemokine CCL2 | 2 | 2018 | 101 | 0.730 |
Why?
|
| Mitochondria | 5 | 2017 | 643 | 0.690 |
Why?
|
| Proteolysis | 4 | 2017 | 97 | 0.670 |
Why?
|
| Neoplasms | 3 | 2022 | 1667 | 0.660 |
Why?
|
| Caspase 3 | 4 | 2013 | 233 | 0.640 |
Why?
|
| Signal Transduction | 9 | 2022 | 2689 | 0.630 |
Why?
|
| Calpain | 4 | 2013 | 205 | 0.620 |
Why?
|
| Oxazoles | 1 | 2016 | 17 | 0.540 |
Why?
|
| Peptide Fragments | 1 | 2018 | 483 | 0.510 |
Why?
|
| Calcium Channel Blockers | 1 | 2016 | 138 | 0.510 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2016 | 56 | 0.510 |
Why?
|
| Imidazoles | 1 | 2016 | 175 | 0.500 |
Why?
|
| Regeneration | 1 | 2015 | 105 | 0.480 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2018 | 46 | 0.450 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 2550 | 0.440 |
Why?
|
| Muscle Fibers, Slow-Twitch | 1 | 2013 | 7 | 0.440 |
Why?
|
| Rats, Sprague-Dawley | 12 | 2020 | 2083 | 0.430 |
Why?
|
| Oxidative Stress | 7 | 2020 | 718 | 0.420 |
Why?
|
| Animals | 20 | 2022 | 20881 | 0.400 |
Why?
|
| Antioxidants | 1 | 2013 | 304 | 0.370 |
Why?
|
| Rats | 12 | 2020 | 5300 | 0.340 |
Why?
|
| Adaptation, Physiological | 2 | 2011 | 189 | 0.340 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 180 | 0.280 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 3 | 2016 | 51 | 0.270 |
Why?
|
| Cytokines | 2 | 2007 | 866 | 0.270 |
Why?
|
| Muscle Contraction | 5 | 2017 | 210 | 0.260 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2005 | 23 | 0.260 |
Why?
|
| Exercise | 2 | 2009 | 658 | 0.250 |
Why?
|
| Female | 17 | 2019 | 38074 | 0.240 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 475 | 0.240 |
Why?
|
| Peptide Hydrolases | 2 | 2016 | 82 | 0.240 |
Why?
|
| Physical Fitness | 1 | 2005 | 117 | 0.240 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 248 | 0.240 |
Why?
|
| Muscle Weakness | 2 | 2015 | 26 | 0.230 |
Why?
|
| Autophagy-Related Protein 5 | 2 | 2020 | 11 | 0.230 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2013 | 69 | 0.220 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 370 | 0.210 |
Why?
|
| Anorexia | 1 | 2022 | 7 | 0.210 |
Why?
|
| Heterografts | 2 | 2019 | 70 | 0.200 |
Why?
|
| Neoplasm Transplantation | 2 | 2019 | 160 | 0.200 |
Why?
|
| Autophagy | 2 | 2020 | 208 | 0.190 |
Why?
|
| Cardiotoxicity | 1 | 2020 | 12 | 0.190 |
Why?
|
| Adipose Tissue | 1 | 2022 | 221 | 0.180 |
Why?
|
| Physical Conditioning, Animal | 2 | 2012 | 34 | 0.180 |
Why?
|
| Mitochondria, Muscle | 2 | 2011 | 12 | 0.180 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 82 | 0.180 |
Why?
|
| NF-kappa B | 3 | 2017 | 432 | 0.180 |
Why?
|
| Gene Ontology | 1 | 2019 | 31 | 0.170 |
Why?
|
| Aging | 1 | 2005 | 911 | 0.170 |
Why?
|
| Humans | 13 | 2022 | 68618 | 0.170 |
Why?
|
| Doxorubicin | 1 | 2020 | 231 | 0.170 |
Why?
|
| Myoblasts | 2 | 2016 | 22 | 0.170 |
Why?
|
| Disease Progression | 2 | 2019 | 1038 | 0.160 |
Why?
|
| Losartan | 2 | 2015 | 45 | 0.160 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2015 | 95 | 0.150 |
Why?
|
| Male | 11 | 2020 | 37321 | 0.150 |
Why?
|
| Transcriptome | 1 | 2019 | 164 | 0.150 |
Why?
|
| Interleukin-8 | 1 | 2017 | 71 | 0.150 |
Why?
|
| Immunologic Surveillance | 1 | 2017 | 10 | 0.150 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2017 | 18 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 508 | 0.150 |
Why?
|
| Enalapril | 2 | 2015 | 86 | 0.140 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 118 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2018 | 330 | 0.140 |
Why?
|
| MyoD Protein | 1 | 2016 | 13 | 0.140 |
Why?
|
| Pancreatectomy | 1 | 2017 | 129 | 0.140 |
Why?
|
| Enzyme Activation | 2 | 2016 | 791 | 0.140 |
Why?
|
| Nutritional Status | 1 | 2017 | 112 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2016 | 82 | 0.140 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2013 | 20 | 0.140 |
Why?
|
| Aged | 6 | 2018 | 14862 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2013 | 89 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 223 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 307 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 331 | 0.120 |
Why?
|
| Mice | 4 | 2019 | 8474 | 0.120 |
Why?
|
| Adrenal Medulla | 1 | 2014 | 5 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 331 | 0.110 |
Why?
|
| Macrophages | 1 | 2017 | 647 | 0.110 |
Why?
|
| Hypothalamus | 1 | 2014 | 78 | 0.110 |
Why?
|
| Physical Endurance | 3 | 2012 | 38 | 0.110 |
Why?
|
| Immobilization | 1 | 2013 | 26 | 0.110 |
Why?
|
| Hindlimb Suspension | 1 | 2013 | 11 | 0.110 |
Why?
|
| Extremities | 1 | 2013 | 49 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 2791 | 0.110 |
Why?
|
| Mitochondria, Heart | 1 | 2012 | 53 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2013 | 753 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2013 | 447 | 0.100 |
Why?
|
| Biomarkers | 2 | 2016 | 1593 | 0.100 |
Why?
|
| Reactive Nitrogen Species | 1 | 2011 | 32 | 0.090 |
Why?
|
| Oligopeptides | 1 | 2011 | 152 | 0.090 |
Why?
|
| Sarcolemma | 1 | 2009 | 16 | 0.080 |
Why?
|
| Middle Aged | 4 | 2018 | 21147 | 0.080 |
Why?
|
| Myofibrils | 1 | 2009 | 35 | 0.080 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2009 | 7 | 0.080 |
Why?
|
| Reperfusion Injury | 1 | 2012 | 320 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1070 | 0.080 |
Why?
|
| Mitochondrial Proteins | 1 | 2009 | 113 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2007 | 4848 | 0.070 |
Why?
|
| Heart Diseases | 1 | 2009 | 276 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 258 | 0.070 |
Why?
|
| Exercise Test | 1 | 2007 | 242 | 0.070 |
Why?
|
| Anaerobic Threshold | 1 | 2005 | 13 | 0.070 |
Why?
|
| Peptidoglycan | 1 | 2005 | 14 | 0.070 |
Why?
|
| Stimulation, Chemical | 1 | 2005 | 57 | 0.070 |
Why?
|
| Weight Lifting | 1 | 2005 | 15 | 0.070 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2005 | 34 | 0.060 |
Why?
|
| Toll-Like Receptors | 1 | 2005 | 56 | 0.060 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2005 | 114 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 191 | 0.060 |
Why?
|
| Adolescent | 2 | 2007 | 8912 | 0.060 |
Why?
|
| Lipopolysaccharides | 1 | 2005 | 455 | 0.060 |
Why?
|
| Myocardium | 1 | 2009 | 1204 | 0.050 |
Why?
|
| Age Factors | 1 | 2007 | 1864 | 0.050 |
Why?
|
| Oxidation-Reduction | 2 | 2016 | 567 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 1054 | 0.050 |
Why?
|
| Inflammation | 1 | 2007 | 1030 | 0.050 |
Why?
|
| Random Allocation | 2 | 2012 | 442 | 0.050 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2020 | 93 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2012 | 954 | 0.040 |
Why?
|
| Adult | 2 | 2007 | 21403 | 0.040 |
Why?
|
| Nutrition Therapy | 1 | 2017 | 21 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2017 | 34 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2017 | 100 | 0.040 |
Why?
|
| Transcription Factor RelB | 1 | 2016 | 4 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2016 | 26 | 0.030 |
Why?
|
| Morpholines | 1 | 2016 | 79 | 0.030 |
Why?
|
| Muscle Development | 1 | 2016 | 31 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 536 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 304 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2018 | 7277 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2016 | 128 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2017 | 382 | 0.030 |
Why?
|
| United States | 1 | 2007 | 7367 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1056 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 626 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Body Weight | 1 | 2016 | 554 | 0.030 |
Why?
|
| Angiotensin II | 1 | 2015 | 220 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 867 | 0.030 |
Why?
|
| Sympathetic Nervous System | 1 | 2014 | 81 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1420 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 1027 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 1692 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 202 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 2093 | 0.030 |
Why?
|
| Caspase Inhibitors | 1 | 2012 | 36 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2673 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2014 | 175 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1174 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 1851 | 0.020 |
Why?
|
| Tripartite Motif Proteins | 1 | 2011 | 7 | 0.020 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2011 | 8 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 3259 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2011 | 94 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 69 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 168 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2012 | 383 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 3705 | 0.020 |
Why?
|
| Actins | 1 | 2011 | 249 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2017 | 1615 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1040 | 0.020 |
Why?
|
| Monoamine Oxidase | 1 | 2009 | 26 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 2009 | 33 | 0.020 |
Why?
|
| Trypsin | 1 | 2009 | 64 | 0.020 |
Why?
|
| Cell Fractionation | 1 | 2009 | 34 | 0.020 |
Why?
|
| Databases, Protein | 1 | 2009 | 49 | 0.020 |
Why?
|
| Ventilator Weaning | 1 | 2009 | 27 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2009 | 54 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2009 | 120 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1200 | 0.020 |
Why?
|
| Cell Respiration | 1 | 2009 | 47 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2009 | 136 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2009 | 76 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 186 | 0.020 |
Why?
|
| Heart Rate | 1 | 2009 | 568 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 947 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 1641 | 0.020 |
Why?
|
| Time Factors | 1 | 2012 | 4655 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2009 | 1451 | 0.010 |
Why?
|